These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 25192810)

  • 1. Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2014 Oct; 22(19):5487-505. PubMed ID: 25192810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.
    Nara H; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    J Med Chem; 2014 Nov; 57(21):8886-902. PubMed ID: 25264600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.
    Nara H; Kaieda A; Sato K; Naito T; Mototani H; Oki H; Yamamoto Y; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    J Med Chem; 2017 Jan; 60(2):608-626. PubMed ID: 27966948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent inhibitors precise to S1' loop of MMP-13, a crucial target for osteoarthritis.
    Kalva S; Saranyah K; Suganya PR; Nisha M; Saleena LM
    J Mol Graph Model; 2013 Jul; 44():297-310. PubMed ID: 23938376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.
    Nara H; Sato K; Kaieda A; Oki H; Kuno H; Santou T; Kanzaki N; Terauchi J; Uchikawa O; Kori M
    Bioorg Med Chem; 2016 Dec; 24(23):6149-6165. PubMed ID: 27825552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents.
    Xie XW; Wan RZ; Liu ZP
    ChemMedChem; 2017 Aug; 12(15):1157-1168. PubMed ID: 28722301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design and optimization of pyrimidine- and 1,2,4-triazolo[4,3-a]pyrimidine-based matrix metalloproteinase-10/13 inhibitors via Dimroth rearrangement towards targeted polypharmacology.
    El Ashry ESH; Awad LF; Teleb M; Ibrahim NA; Abu-Serie MM; Abd Al Moaty MN
    Bioorg Chem; 2020 Mar; 96():103616. PubMed ID: 32032847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Based Design and Synthesis of Potent and Selective Matrix Metalloproteinase 13 Inhibitors.
    Choi JY; Fuerst R; Knapinska AM; Taylor AB; Smith L; Cao X; Hart PJ; Fields GB; Roush WR
    J Med Chem; 2017 Jul; 60(13):5816-5825. PubMed ID: 28653849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis.
    Schnute ME; O'Brien PM; Nahra J; Morris M; Howard Roark W; Hanau CE; Ruminski PG; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Patt WC; Shieh HS; Collins B; Pavlovsky AG; Palmquist KE; Aston KW; Hitchcock J; Rogers MD; McDonald J; Johnson AR; Munie GE; Wittwer AJ; Man CF; Settle SL; Nemirovskiy O; Vickery LE; Agawal A; Dyer RD; Sunyer T
    Bioorg Med Chem Lett; 2010 Jan; 20(2):576-80. PubMed ID: 20005097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virtual Screening on MMP-13 Led to Discovering New Inhibitors Including a Non-Zinc Binding and a Micro Molar One: A Successful Example of Receptor Selection According to Cross-Docking Results for a Flexible Enzyme.
    Ramezani M; Shamsara J
    Comb Chem High Throughput Screen; 2017; 20(8):719-725. PubMed ID: 28814230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13.
    Taylor SJ; Abeywardane A; Liang S; Muegge I; Padyana AK; Xiong Z; Hill-Drzewi M; Farmer B; Li X; Collins B; Li JX; Heim-Riether A; Proudfoot J; Zhang Q; Goldberg D; Zuvela-Jelaska L; Zaher H; Li J; Farrow NA
    J Med Chem; 2011 Dec; 54(23):8174-87. PubMed ID: 22017539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Virtual High-Throughput Screening for Matrix Metalloproteinase Inhibitors.
    Choi JY; Fuerst R
    Methods Mol Biol; 2017; 1579():259-271. PubMed ID: 28299742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic characterization of 4,4'-biphenylsulfonamides as selective non-zinc binding MMP inhibitors.
    Santamaria S; Nuti E; Cercignani G; La Regina G; Silvestri R; Supuran CT; Rossello A
    J Enzyme Inhib Med Chem; 2015 Dec; 30(6):947-54. PubMed ID: 25694065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for the highly selective inhibition of MMP-13.
    Engel CK; Pirard B; Schimanski S; Kirsch R; Habermann J; Klingler O; Schlotte V; Weithmann KU; Wendt KU
    Chem Biol; 2005 Feb; 12(2):181-9. PubMed ID: 15734645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis of derivatives of methyl rosmarinate and their inhibitory activities against matrix metalloproteinase-1 (MMP-1).
    Yuan H; Lu W; Wang L; Shan L; Li H; Huang J; Sun Q; Zhang W
    Eur J Med Chem; 2013 Apr; 62():148-57. PubMed ID: 23353736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.
    Blagg JA; Noe MC; Wolf-Gouveia LA; Reiter LA; Laird ER; Chang SP; Danley DE; Downs JT; Elliott NC; Eskra JD; Griffiths RJ; Hardink JR; Haugeto AI; Jones CS; Liras JL; Lopresti-Morrow LL; Mitchell PG; Pandit J; Robinson RP; Subramanyam C; Vaughn-Bowser ML; Yocum SA
    Bioorg Med Chem Lett; 2005 Apr; 15(7):1807-10. PubMed ID: 15780611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis.
    Ruminski PG; Massa M; Strohbach J; Hanau CE; Schmidt M; Scholten JA; Fletcher TR; Hamper BC; Carroll JN; Shieh HS; Caspers N; Collins B; Grapperhaus M; Palmquist KE; Collins J; Baldus JE; Hitchcock J; Kleine HP; Rogers MD; McDonald J; Munie GE; Messing DM; Portolan S; Whiteley LO; Sunyer T; Schnute ME
    J Med Chem; 2016 Jan; 59(1):313-27. PubMed ID: 26653735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
    Senn N; Ott M; Lanz J; Riedl R
    J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fragment-Based Discovery of 5-Arylisatin-Based Inhibitors of Matrix Metalloproteinases 2 and 13.
    Agamennone M; Belov DS; Laghezza A; Ivanov VN; Novoselov AM; Andreev IA; Ratmanova NK; Altieri A; Tortorella P; Kurkin AV
    ChemMedChem; 2016 Sep; 11(17):1892-8. PubMed ID: 27418256
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationship of fused-pyrimidine derivatives as a series of novel GPR119 agonists.
    Negoro K; Yonetoku Y; Moritomo A; Hayakawa M; Iikubo K; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Nov; 20(21):6442-51. PubMed ID: 23010456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.